347 related articles for article (PubMed ID: 31710121)
1. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
Vachher M; Arora K; Burman A; Kumar B
J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
3. NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma.
Guo Q; Han N; Shi L; Yang L; Zhang X; Zhou Y; Yu S; Zhang M
Oncol Rep; 2019 Sep; 42(3):963-972. PubMed ID: 31322259
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
6. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
7. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
8. ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas.
Fan X; Wang Y; Zhang C; Liu L; Yang S; Wang Y; Liu X; Qian Z; Fang S; Qiao H; Jiang T
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27571068
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional expression of ZICs as an independent indicator of survival in gliomas.
Han Z; Jia J; Lv Y; Wang R; Cao K
Sci Rep; 2021 Sep; 11(1):17532. PubMed ID: 34475426
[TBL] [Abstract][Full Text] [Related]
10. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
12. Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis.
Hagemann C; Fuchs S; Monoranu CM; Herrmann P; Smith J; Hohmann T; Grabiec U; Kessler AF; Dehghani F; Löhr M; Ernestus RI; Vince GH; Stein U
Neuro Oncol; 2013 Dec; 15(12):1696-709. PubMed ID: 24220141
[TBL] [Abstract][Full Text] [Related]
13. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value.
Reddy PS; Umesh S; Thota B; Tandon A; Pandey P; Hegde AS; Balasubramaniam A; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
Cancer Biol Ther; 2008 May; 7(5):663-8. PubMed ID: 18728403
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
[TBL] [Abstract][Full Text] [Related]
15. Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
Tu Y; He S; Fu J; Li G; Xu R; Lu H; Deng J
Clin Transl Oncol; 2012 Mar; 14(3):214-20. PubMed ID: 22374425
[TBL] [Abstract][Full Text] [Related]
16. Identification of Autophagy-Related Prognostic Signature and Analysis of Immune Cell Infiltration in Low-Grade Gliomas.
Quan Q; Xiong X; Wu S; Yu M
Biomed Res Int; 2021; 2021():7918693. PubMed ID: 34790823
[TBL] [Abstract][Full Text] [Related]
17. GRN is a prognostic biomarker and correlated with immune infiltration in glioma: A study based on TCGA data.
Xu SM; Xiao HY; Hu ZX; Zhong XF; Zeng YJ; Wu YX; Li D; Song T
Front Oncol; 2023; 13():1162983. PubMed ID: 37091137
[TBL] [Abstract][Full Text] [Related]
18. Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis.
Reon BJ; Anaya J; Zhang Y; Mandell J; Purow B; Abounader R; Dutta A
PLoS Med; 2016 Dec; 13(12):e1002192. PubMed ID: 27923049
[TBL] [Abstract][Full Text] [Related]
19. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
20. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
